About Sonja Nelson
Sonja Nelson is a chief financial officer at CoRegen.
Sonja Nelson reports to the SEC as a director or officer of 4 public companies, including Motus GI (MOTS), Ambrx Biopharma (AMAM) and Ambrx Biopharma (AMAM).
Sonja Nelson first appears on SEC filings in 2016.
Experience
This experience comes from Sonja Nelson's profile and from SEC filings. For roles taken from filings, the years are when the filings name Sonja Nelson in the role, so the role may have started earlier or lasted longer.
CoRegen, Inc. Current
Chief Financial Officer
2025 – Present · Houston, TX
Develops immune cell therapies for people with cancer.
AI
Ambrx Biopharma, Inc.
Chief Financial Officer
2021 – 2025 · Public company (AMAM)
MI
Motus GI Holdings, Inc.
Board member, Audit Committee Chair
2021 – 2024 · Public company (MOTS)
AI
Ambrx Biopharma Inc.
Chief Financial Officer
2023 · Public company (AMAM)
II
ImmunityBio, Inc.
Chief Financial Officer
2016 – 2021 · Public company (IBRX)
NA
NantKwest
Chief Financial Officer
2015 – 2021
AL
AltheaDx
VP/Corporate Controller
2014 – 2015
CP
Cadence Pharmaceuticals
Corporate Controller
2012 – 2014
CC
Cricket Communications
Director General Accounting
2008 – 2012
II
ista North America, Inc.
Vice President Finance / Corporate Secretary
2002 – 2008
KL
KPMG LLP
Public Accounting in Germany & US
1998 – 2002
Key Colleagues at Startups
The people Sonja Nelson works with at each company, as listed on that company's latest Form D.
CoRegen, Inc. · Form D, Feb 26, 2026
JS
Jonathan Simons
Board Member
Steve Gorlin
Vice Chairman & President
BM
Bert O'Malley
Director
Suneet Varma
Chairman of the Board
WP
William Haseltine, PhD.
Director
Sonal Gupta
Chief Medical Officer
LF
Lee Fleisher
Board Member
EJ
Edward Benz, Jr.
Director
Peter Gelinas
Chief Technical Officer